Why and how have drug discovery strategies in pharma changed? What are the new mindsets?

被引:53
|
作者
Mignani, Serge [1 ]
Huber, Scot [2 ]
Tomas, Helena
Rodrigues, Joao [3 ]
Majoral, Jean-Pierre [4 ,5 ]
机构
[1] Univ Paris 05, CNRS UMR 860, Lab Chim & Biochim Pharmacol & Toxicol, PRES Sorbonne Paris Cite, 45 Rue St Peres, F-75006 Paris, France
[2] SCYNEXIS Inc, POB 12878, Res Triangle Pk, NC 27709 USA
[3] Univ Madeira, CQM, MMRG, Campus Univ Penteada, P-9000390 Funchal, Portugal
[4] CNRS, Lab Chim Coordinat, 205 Route Narbonne,BP 44099, F-31077 Toulouse 4, France
[5] Univ Toulouse, UPS, INPT, F-31077 Toulouse 4, France
关键词
CHEMICAL BEAUTY; OPEN INNOVATION; 1ST-IN-CLASS; CHALLENGES; REVOLUTION; IMPACT; SPACE;
D O I
10.1016/j.drudis.2015.09.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the pharmaceutical industry the long-term challenge of drug innovation is the key phrase throughout R&D that refers to increasing the output of original drug candidate molecules. To increase R&D productivity, implementation of new and strategic R&D orientations to develop new approaches or systems to identify hits and leads efficiently has taken place and enabled all scientists working in the drug discovery domain to develop innovative medicines for the 21st century.
引用
收藏
页码:239 / 249
页数:11
相关论文
共 50 条